Experiment 66690
Worktypes
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Empty organism |
| Citation | SHOSKES,DA: ZEITLIN,SI: SHAHED,A: RAJFER,J:. (1999). QUERCETIN IN MEN WITH CATEGORY III CHRONIC PROSTATITIS: A PRELIMINARY PROSPECTIVE, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.. 54(6) |
| Amount utilized | |
| Compound isolated | |
| Disease | IN A PROSPECTIVE RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL 30 MEN WITH CATEGORY ILLA AND ILLB CHRONIC PAIN SYNDROME WERE RANDOMIZED IN A DOUBLE-BLIND FASHION TO RECEIVE EITHER PLACEBO OR THE BIOFLAVONOID QUERCETIN 500 MG GWICE DAILY FOR 1 MONTH. THE NIH CHRONIC PROSTATITIS SYMPTOM SCORE WAS USED TO GRADE SYMPTOMS AND THE QUALITY-OF-LIFE IMPACT AT THE START AND CONCLUSION OF THE STUDY. IN A FOLLOW-UP UNBLIND, OPEN-LABEL STUDY, 17 ADDITIONAL MEN RECEIVED 1 MONTH OF A SUPPLEMENT CONTAINING QUERCETIN, AS WELL AS BROMELAIN AND PAPAIN (PROSTA-Q), WHICH ENHANCE BIOFLAVONOID ABSORPTION. PATIENTS TAKING PLACEBO HAD A MEAN IMPROVEMENT IN NIH SYMPTOM SCORE FROM 20.2 TO 18.8 (NOT SIGNIFICANT). WHILE THOSE TAKING THE BIOFLAVONOID HAD A MEAN IMPROVEMENT FROM 21.0 TO 13.1(P = 0.003). 20% OF PATIENTS TAKING PLACEBO AND 67% OF PATIENTS TAKING THE BIOFLAVONOID HAD AN IMPROVEMENT OF SYMPTOMS OF AT LEAST 25%. IN THE 17 PATIENTS WHO RECEIVED PROSTA-Q IN THE OPEN-LABEL STUDY. 82% HAD AT LEAST A 25% IMPROVEMENT IN SYMPTOM SCORE. |
| Dose amount | 1.0 GM |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Gender | MALE |